Abbott is set to join forces with liquid biopsy medtech firm Angle to collaborate on a study into metastatic breast cancer, it has emerged.
As aprt of a research grant, Abbott will provide Angle with its PathVysion HER-2 DNA FISH Probe kits, to be used in the analysis of circulating tumour cells (CTCs).
When applied to tumour cells collected with solid tissue biopsy, FISH, or fluorescence in situ hybridisation, analysis is used to determine the right cancer treatment. In Angle’s study, this analysis is one of the exploratory endpoints.
